Patel Sanj K

Chairman & CEO Patel Sanj K sells entire 48,565-share stake at $54.02, leaving zero holdings; stock now at $55.27.

Patel liquidated his entire position of 48,565 shares for $2,623,481.30 at $54.02 on 2026-05-01, moving from a full stake to zero holdings. The sale occurred approximately $1.25 below the current price of $55.27 and roughly 25.8% below the 90-day return on KNSA shares, suggesting potential underexecution on timing given recent momentum. More striking is the pattern at KNSA specifically: this is the fifth discrete sale in as many trading days (2026-04-28 through 2026-04-30), indicating systematic liquidation of the CEO's entire investment rather than a routine single transaction. While his cross-ticker track record shows 18 prior sells with a 25.00% well-timed rate, the lack of prior measurable outcomes from his same-ticker KNSA sales limits confidence in any pattern at this specific ticker. The company's strong fundamentals—$214.3M quarterly revenue, +60.1% annual growth, and $22.6M net income—are consistent with the elevated stock price, yet the complete divestiture by its chairman and CEO merits investor attention given the concentrated commitment signal it contradicts.

CEO Patel sells entire 508,339-share position for $26,415,228.13 across 6 transactions, exiting stake completely.

Sanj K Patel, Chairman & CEO of Kiniksa Pharmaceuticals International, plc, executed 6 separate sales totaling 508,339 shares for $26,415,228.13 across April 28–30, 2026, at prices ranging from $50.43 to $54.02. This represents a complete exit of his holdings, reducing his position to 0 shares from a pre-transaction base of 508,339 shares (−100.0% of his prior holdings). The company's fundamentals show strong growth with annual revenue of $214,266,000.00 and net income of $22,592,000.00, with annual revenue growth of +60.1%, yet the CEO has divested entirely during a period when the stock trades near its 52-week high of $53.85. Prior trades at this ticker show a pattern of poorly timed sells: all 5 prior KNSA sales generated positive 90-day returns (ranging from +0.2% to +22.8%), indicating the stock subsequently rose after each exit. The current price of $53.78 sits −0.1% from the 52-week high, and the 90-day return has been +22.4%, consistent with this pattern of upward drift post-sale.

KNSA CEO Patel sold 257,969 shares (258.0K) for $10,023,531.59 ($10.0M) over 3 days at $38.86 avg, reducing holdings by 69.8%.

Sanj K Patel, KNSA's Chairman & CEO, executed 4 separate sales totaling 257,969 shares for $10,023,531.59 between October 20–22, 2025, substantially reducing his stake from 369,763 shares to 111,794 shares. The sales occurred near the 52-week high ($38.99), with the blended average price of $38.86 only 0.2% below the peak. While Patel's cross-ticker track record shows mixed timing (37.50% well-timed at the 90-day mark with +6.9% average 90d return), his prior trades at KNSA have been inconsistent—only 2 of 5 prior sales exhibited positive 90-day returns, and his most recent 2025 May sales were followed by strong gains (+22.3% to +24.4% at 90 days). Fundamentally, KNSA is growing revenue aggressively (+56.6% annually) but remains unprofitable on a full-year basis, despite recent quarterly profitability of $17.8M on $156.8M revenue, creating an uncertain risk-reward profile at peak valuations.

KNSA CEO Patel sold 86,270 shares for $2,349,981.45 across 3 transactions (May 23–28), cutting holdings by 47.2%

CEO Sanj K Patel executed 3 separate sales totaling 86,270 shares for $2,349,981.45 between May 23 and May 28, 2025, reducing his stake from 182,944 shares to 96,674 shares. The blended average price of $27.24 represents sales very close to the current price of $27.26 and within 1.9% of the 52-week high, occurring after the stock rallied +27.0% over the prior 30 days and +38.9% over 90 days. At the same ticker over five prior sales, the insider's timing has been mixed: 3 of 5 prior KNSA sells were well-timed at the 90-day mark (stock declined after), while 2 were poorly timed (stock rose after). The company reported strong revenue growth of +56.6% year-over-year and achieved net income of $8,539,000 in the latest quarter, though it remains unprofitable on a full-year basis. The substantial reduction in CEO ownership—nearly half his holdings—represents a material capital redeployment during a period of elevated valuations and recent strong price appreciation.

KNSA CEO Sanj K Patel sold 89,561 shares at $23.00 (-53.0% of holdings) for $2,059,903.00; stock -8.3% in 30d

CEO Sanj K Patel executed a substantial reduction in his KNSA position, selling 89,561 shares at $23.00 on 2024-11-06 and retaining 79,551 shares post-transaction. The sale represents a -53.0% reduction in pre-transaction holdings. Since the sale, the stock has declined -8.3% over 30 days and -9.2% over 90 days, currently trading at $22.86 versus the transaction price of $23.00. Patel's same-ticker history at KNSA shows mixed timing outcomes: 2 of his 4 prior sells were well-timed at the 90-day mark, though his most recent prior sales on 2024-07-23 were followed by stock gains (+12.7% and +4.6% at 90 days), suggesting inconsistent predictability. The company's fundamentals show revenue growth of +22.7% (annual basis) and latest quarterly revenue of $112,214,000.00, but the business is unprofitable (net income $-12,693,000.00 in the latest quarter) with a notably elevated P/E of 114.30.

Kiniksa CEO Patel sold 136,124 shares for $3.5M in 3 separate transactions; holdings decline 68.4% to 63,012 shares

Patel Sanj K, Chairman & CEO, executed 3 separate sales on 2024-07-23 totaling 136,124 shares for $3,491,947.24, reducing his holdings from 199,136 shares to 63,012 shares—a 68.4% reduction. The transactions occurred at blended average price $25.65, near the current price of $25.91 and within 1.4% of the 52-week high of $26.29, suggesting execution near peak valuation. His prior open-market sell at this ticker on 2024-03-07 exhibited a 90-day return of -6.2%, a pattern flagged as well-timed (negative return post-sale). The stock has rallied 36.6% over the past 30 days and 44.9% over 90 days, placing this sale at an elevated price point in the recent recovery. With P/E of 129.55 and net losses of $-3.9M in the latest quarter offsetting revenue growth of 22.7%, the timing proximity to the 52-week high and the substantial reduction in stake size warrant investor attention to position changes at the executive level.